[18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice

• Type of Material: Article
• Authors: Ida Wong-Sefidan, University of California at San Diego; Michelle Byrtek, Genentech Inc.; Xiaolei Zhou, RTI Health Solutions; Jonathan W. Friedberg, University of Rochester; Christopher R Flowers, Emory University; Andrew D. Zelenetz, Memorial Sloan-Kettering Cancer Center; Keith L. Dawson, Genentech Inc.; Erin Reid, University of California at San Diego
• Language: English
• Date: 2017-01-01
• Publisher: Taylor & Francis: STM, Behavioural Science and Public Health Titles
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
• Final Published Version (URL): http://dx.doi.org/10.1080/10428194.2016.1213824
• Title of Journal or Parent Work: Leukemia & Lymphoma
• ISSN: 1042-8194
• Volume: 58
• Issue: 4
• Start Page: 809
• End Page: 815
• Grant/Funding Information: This study was funded by Genentech Inc. (South San Francisco, CA, USA).; Support for editorial assistance was funded by Genentech Inc.
• Keywords: Hematology; UNITED-STATES; prognostic; PET-CT; Life Sciences & Biomedicine; NATIONAL LYMPHOCARE; survival; PET; Science & Technology; MANAGEMENT; Oncology; Follicular lymphoma; IMPACT
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

Positron emission tomography (PET) after induction therapy in follicular lymphoma (FL) is predictive of survival in clinical trials. We describe use of PET and computed tomography (CT) after rituximab-based induction therapy in FL patients followed by the National LymphoCare Study and explore the association between imaging response assessment and survival. Among 1289 patients, imaging consisted of: PET ± CT (35%), CT alone (42%), other/no imaging (24%). Median follow-up was 7.6 years. In unadjusted analyses, positive PET ± CT and CT were prognostic of inferior OS (HR 1.78; 95% CI: 1.16–2.72 and HR 1.61, 95% CI: 1.13–2.29, respectively) and PFS (HR 1.63, 95% CI: 1.21–2.20 and HR 1.45, 95% CI: 1.12–1.89, respectively). Adjusting for FL International Prognostic Index, PET remained predictive of OS (HR 1.54, 95% CI: 1.01–2.36) and PFS (HR 1.54, 95% CI: 1.14–2.07). Residual disease via PET in FL is prognostic of survival in clinical practice.